Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Microbiome Cancer Immunotherapy Project Aims To Improve Oncology Drugs

XTALKS VITALS NEWS

Microbiome

While the immunotherapies will be aimed at improving the efficacy of currently-available oncology drugs, they could also act as monotherapeutics for cancer treatment.

Tweetables from this article:

Tweet: New class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs http://ctt.ec/5a6gw+New class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs.

Tweet: Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases http://ctt.ec/5md0J+Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases.

Share this!

August 15, 2016 | by Sarah Massey, M.Sc.

A new class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs, are set to be developed by Vedanta Biosciences and NYU Langone Medical Center. While the immunotherapies will be aimed at improving the efficacy of currently-available oncology drugs, they could also act as monotherapeutics for cancer treatment.

Earlier this year, Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases. The company – founded by PureTech Health – hopes to get these drugs into the clinic in 2017.

“Dr. Weber is a pioneer in translational research, particularly in immunotherapy and the development of checkpoint inhibitors,” said CSO of Vedanta, Bruce Roberts, commenting on the leader of the project. “We look forward to working with Dr. Weber to expand Vedanta’s portfolio of immune activating microbial cocktails for use in standalone immunotherapy and in combination with checkpoint inhibitors.”



Verdanta’s interest in oncology comes at a turbulent time in microbiome therapeutics research. A Phase II clinical trial of an oral microbiome drug, led by Seres Therapeutics, failed to meet its endpoint of reducing the risk of Clostridium difficile infection.

The company’s collaboration with NYU aims to investigate the mechanisms by which gut bacteria impact checkpoint inhibitor drug efficacy as a cancer therapy. Vedanta researchers believe that human gut bacteria could be harnessed to develop effective immunotherapies.

“Checkpoint inhibitors are a major advance in cancer therapy, but many patients do not respond to therapy, and some patients who respond will eventually relapse,” said Dr. Jeffrey Weber, who is the deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone. “Recent data suggest an important role for the microbiome in the anti-tumor activity of immunotherapy, and our other studies of the microbiome will offer interesting new clinical insights into how and why these treatments work.”


Keywords: Microbiome, Immunotherapy, Oncology


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.